Acute coronary syndrome after infliximab infusion

Cardiology in Review

Volumn 14, Issue 1, 2006, Pages 50-52

  Abedin, Moeen ^a   Scheurich, Daniel ^a   Reimold, Sharon C ^a   Reimold, Andreas M ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Biologics; Crohn disease; Myocardial infarction; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CAPTOPRIL; DIPHENHYDRAMINE; GLYCERYL TRINITRATE; HEPARIN; INFLIXIMAB; METHOTREXATE; METOPROLOL; PARACETAMOL; SIMVASTATIN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LABORATORY TEST; PAIN; PHYSICAL EXAMINATION; PHYSICIAN; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; VITAL SIGN; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART CATHETERIZATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; SYNDROME;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; SYNDROME;

EID: 33644876657     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000178320.51474.ac     Document Type: Article

References (9)

1. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-1939.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
3. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002;29:667-677.
4. Kavanaugh A, Cush JJ, Matteson E. FDA Meeting March 2003: Update on the Safety of New Drugs for Rheumatoid Arthritis. American College of Rheumatology Hotline; 2003.
5. Chung ES, Packer M, Lo KA, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
6. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
7. Remicade Prescribing Information. Malvern, PA: Centocor; April 2003.
8. Feldmann M, Maini RN Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-196.
9. Bacon PA, Townend JN. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum. 2001;44:2707-2710.